Presage Biosciences presents data demonstrating superior tumour growth inhibition by voruciclib and proteasome inhibitors
Data presented at AACR Annual Meeting from CIVO platform.
Presage Biosciences will present preclinical data showing that the company’s clinical-stage oral CDK inhibitor, voruciclib, in combination with proteasome inhibitors, demonstrated superior tumour growth inhibition in xenografts than the single agents separately in a model of triple negative breast cancer (TNBC), a disease which has proven challenging to treat with standard chemotherapy options. The data are being presented today at the American Association for Cancer Research (AACR) 2016 Annual Meeting in New Orleans.
In a poster presentation entitled “Voruciclib, a clinical stage CDK inhibitor sensitizes triple negative breast cancer xenografts to proteasome inhibition,” Presage researchers present results from a study using the Presage CIVO platform, which allows for simultaneous assessment of multiple drugs or drug combinations directly in a single solid tumor, to identify drug combinations with voruciclib that result in synergistic anti-tumor activity in the HCC1187 model of triple negative breast cancer:
- Injecting voruciclib and bortezomib in combination directly into tumours led to robust localized anti-tumour activity.
- In contrast, exposure to either voruciclib or bortezomib as single agents showed limited anti-tumour activity.
- The combination effect with voruciclib also was present when injected in combination with other proteasome inhibitors, including next-generation oral proteasome inhibitor MLN2238.
- Again, no significant impact on tumour progression was observed in xenografted subjects treated with either voruciclib or MLN2238 as single agents.
Presage is developing voruciclib, a clinical-stage oral CDK inhibitor, in combination with other agents identified through CIVO, an in vivo assessment technology intended for drug development to enable the first side-by-side comparison of multiple drugs and combinations within a single living tumor while still in a patient’s body, without exposing the patient to the toxicity associated with systemically dosed drugs.
“The CIVO platform has enabled us to rapidly gain a better understanding of the unique biology of tumour response to voruciclib, particularly in combination with other agents,” said Nathan Caffo, President of Presage. “We expect to apply these findings as Presage develops voruciclib drug combinations in the clinic to hopefully provide more effective treatments for patients with cancer.”
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance